HAVCR2 and ovarian carcinoma: In this study, we demonstrate that combined anti-TIM-3/CD137 mAbs inhibited the outgrowth of ID8 ovarian cancer cells injected 10 days previously, resulting in the long-lasting survival of 60% of mice while either mAb alone was ineffective in tumor protection.